Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer: A Phase I/II Feasibility Study

NCT07643012 is registered in ClinicalTrials.gov with Rutgers, The State University of New Jersey as lead sponsor.

NCT NCT07643012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07643012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer: A Phase I/II Feasibility Study
Lead sponsor
Rutgers, The State University of New Jersey
Phase
Not applicable
Overall status
Recruiting
Start date
June 9, 2026
Completion date
June 30, 2029
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer